Page last updated: 2024-12-06

rhodamine 123

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rhodamine 123 is a cationic fluorescent dye that is commonly used as a mitochondrial probe. It is synthesized by reacting rhodamine B with thionyl chloride, followed by treatment with 3-aminopropanol. Rhodamine 123 accumulates in mitochondria due to its positive charge and its ability to bind to negatively charged mitochondrial membranes. This accumulation results in an increase in fluorescence intensity, which can be used to monitor mitochondrial function. Rhodamine 123 has been shown to inhibit mitochondrial respiration, leading to apoptosis. It has also been shown to have anti-tumor activity in vitro and in vivo. Rhodamine 123 is widely studied as a potential therapeutic agent for cancer, as well as a tool for studying mitochondrial function and dynamics.'

Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65217
CHEMBL ID245839
SCHEMBL ID37743
SCHEMBL ID18816029
PubMed CID4541001
CHEMBL ID1182558
CHEBI ID52894
SCHEMBL ID12994563
MeSH IDM0029850
PubMed CID9929799
CHEMBL ID176049
CHEBI ID8828
SCHEMBL ID3808879
MeSH IDM0029850

Synonyms (85)

Synonym
3,6-diamino-9-(2-(methoxycarbonyl)phenyl)xanthylium chloride
6-amino-9-[2-(methoxycarbonyl)phenyl]-3h-xanthen-3-iminium chloride
CHEMBL245839
3,6-diamino-9-[2-(methoxycarbonyl)phenyl]xanthylium chloride
AKOS015958728
AKOS015917525
2-(6-amino-3-imino-3h-xanthen-9-yl)benzoic acid methyl ester
SCHEMBL37743
R-4500
CS-7693
SCHEMBL18816029
HY-D0816
DTXSID00886503
3,6-diamino-9-(2-methoxycarbonyl-phenyl)-xanthenylium; chloride
AMY40920
r-22420
r-22420rh-123
rhodamin 123 chloride
[6-amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium;chloride
3,6-diamino-9-[2-(methoxycarbonyl)phenyl]-10lambda4-xanthen-10-ylium chloride
EN300-21633980
rhodamine 123
smr001223890
MLS001360432 ,
[6-amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium
CHEBI:52894
rhodamine 123(1+)
6-amino-9-[2-(methoxycarbonyl)phenyl]-3h-xanthen-3-iminium
rhodamine 123 cation
rhodamine-123
xanthylium,3,6-diamino-9-[2-(methoxycarbonyl)phenyl]-
rhodamine123
gtpl4607
cid_24207752
[6-amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium;chloride;hydrate
[6-azanyl-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium;chloride;hydrate
[6-amino-9-(2-methoxycarbonylphenyl)-3-xanthenylidene]ammonium;chloride;hydrate
bdbm74350
[6-amino-9-(2-carbomethoxyphenyl)xanthen-3-ylidene]ammonium;chloride;hydrate
CHEMBL1182558
SCHEMBL12994563
Q27088547
AKOS040742549
rhodamine 123? (chloride)
C16107
rhodamine 123, mitochondrial specific fluorescent dye
2-(6-amino-3-imino-3h-xanthen-9-yl)benzoic acid methyl ester monohydrochloride
benzoic acid, 2-(6-amino-3-imino-3h-xanthen-9-yl)-, methyl ester, monohydrochloride
xanthylium, 3,6-diamino-9-(2-(methoxycarbonyl)phenyl)-, chloride
einecs 263-687-8
CHEBI:8828 ,
rhodamine 110 methyl ester
rhodamine 123, bioreagent, for fluorescence, >=85% (hplc)
CHEMBL176049
S3577
unii-1n3cz14c5o
1n3cz14c5o ,
r 302
xanthylium, 3,6-diamino-9-(2-(methoxycarbonyl)phenyl)-, chloride (1:1)
r 22420
F9995-1239
methyl 2-(6-amino-3-imino-3h-xanthen-9-yl)benzoate hydrochloride
xanthylium, 3,6-diamino-9-[2-(methoxycarbonyl)phenyl]-, chloride
3,6-diamino-9-(2-(methoxycarbonyl)phenyl)(xanthylium chloride (1:1)
rhodamine 123 [mi]
rh-123
methyl 2-(6-amino-3'-imino-3h-xanthen-9-yl)benzoate hydrochloride
SCHEMBL3808879
AKOS024282728
mfcd00012664
VU0549452-1
rhodamine methylester hydrochloride
AS-72513
rhodamine methyl ester hydrochloride
methyl 2-(6-amino-3-imino-3h-xanthen-9-yl)benzoate--hydrogen chloride (1/1)
108608-81-7
DTXSID90910785
r 22420; r 302; rh 123
BCP22573
Q3429577
EX-A1709
methyl o-(6-amino-3'-imino-3h-xanthen-9-yl) benzoate monohydrochloride
rh-123;r-22420
rh-123; r-22420
methyl 2-(3-amino-6-iminoxanthen-9-yl)benzoate;hydrochloride

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Mechanistically based short-term in vitro tests to evaluate the relative cytotoxicity of of chemicals will complement in vitro genotoxicity testing during the initial phases of toxicity evaluation as well as provide information on the cellular site of action for chemicals found to be toxic in animals."( Assessment of mitochondrial membrane potential as an indicator of cytotoxicity.
Bombick, DW; Doolittle, DJ; Rahn, CA, 1991
)
0.28
" These results demonstrate that the most toxic substance for growing fibroblasts was the solvent DMSO."( Toxicity in vital fluorescence microscopy: effect of dimethylsulfoxide, rhodamine-123, and DiI-low density lipoprotein on fibroblast growth in vitro.
Braunwald, NS; Crawford, JM, 1991
)
0.28
" This adverse effect exerted by SP562, however, was not as strong as that caused by (+/-) gossypol acetic acid of the same molarity."( Adverse effects of gossypol analogs on TM4 cell mitochondrial function.
Fitzgerald, LM; Tanphaichitr, N, 1989
)
0.28
" At doses of rhodamine 123 which were toxic to carcinoma cells, the conversion of mitochondrial-specific to cytoplasmic-nonspecific localization of the drug was observed prior to cell death."( Selective toxicity of rhodamine 123 in carcinoma cells in vitro.
Bernal, SD; Chen, LB; Lampidis, TJ; Summerhayes, IC, 1983
)
0.27
" Higher DECA doses under either regimen induced severe toxic effects and mortality."( Toxicity of the mitochondrial poison dequalinium chloride in a murine model system.
Emma, DA; Fuchtner, C; Gamboa-Vujicic, G; Liao, SY; Manetta, A, 1993
)
0.29
" However, tamoxifen alone caused significant toxic effects to TSGH-8301 at > or = 40 microM and to HTB9 at > or = 30 microM."( Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Cheng, AL; Hsieh, CY; Hsieh, TS; Lai, MK; Pu, YS; Su, IJ; Tsai, TC; Tseng, NF, 1996
)
0.29
"Tamoxifen enhanced the cytotoxicity of chemotherapeutic agents largely through its toxic effects on the bladder cancer cells."( Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Cheng, AL; Hsieh, CY; Hsieh, TS; Lai, MK; Pu, YS; Su, IJ; Tsai, TC; Tseng, NF, 1996
)
0.29
"Comparative kinetic analyses of the mechanisms of toxicity of the alkylphenol eugenol and its putative toxic metabolite (quinone methide, EQM) were carried out in cultured rat liver cells (Clone 9, ATCC) using a variety of vital fluorescence bioassays with a Meridian Ultima laser cytometer."( Comparative toxicity of eugenol and its quinone methide metabolite in cultured liver cells using kinetic fluorescence bioassays.
Barhoumi, R; Burghardt, RC; Thompson, DC, 1998
)
0.3
" Thus, the aim of the present work was to evaluate P-gp expression and activity in Caco-2 cells exposed to doxorubicin (a known P-gp inducer) and to correlate these changes with paraquat toxic effects."( In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells.
Bastos, Mde L; Carmo, H; Carvalho, F; Cordeiro-da-Silva, A; Dinis-Oliveira, R; Lima, SC; Remião, F; Silva, R, 2011
)
0.37
"The beneficial or adverse effects of isolated phytochemicals are not always concordant with effects of the botanical dietary supplements from which they were derived."( Use of the Combination Index to determine interactions between plant-derived phenolic acids on hepatotoxicity endpoints in human and rat hepatoma cells.
Ferguson, MS; Flynn, TJ; Hoagland, EM; Liu, Y, 2013
)
0.39
" In conclusion, the study demonstrated the potential of the tested thioxanthonic compounds in protecting against toxic effects induced by P-gp substrates through P-gp induction and activation."( P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity.
Barbosa, DJ; Bastos, Mde L; Carmo, H; Gameiro, M; Gomes, A; Paiva, AM; Palmeira, A; Pinto, M; Remião, F; Silva, R; Sousa, E, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" In conclusion, it was demonstrated that DEX pretreatment affects not only P-gp-mediated disposition of Rho123 but also pharmacokinetic interactions of P-gp/CYP3A-related compounds with Rho123, probably because concentrations of substrates/inhibitors at target sites such as the intestine and liver are varied."( Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Murakami, T; Nagai, J; Nasu, R; Sanemasa, M; Takano, M; Yumoto, R, 2001
)
0.31
" Comparison of the pharmacokinetic parameters of omeprazole before and after fexofenadine revealed that there were no differences in peak concentration, time to peak concentration, area under the time concentration curve up to 8 hr, and elimination half-life."( Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.
Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N; Yoshiya, G, 2004
)
0.32
"The purpose of the present study was to evaluate the effect of kainic acid (KA)-induced acute seizures on the pharmacokinetic profiles of antiepileptic drug, carbamazepine (CBZ) in mice."( Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures.
Honda, N; Nishimura, A; Shibata, N; Sugioka, N; Takada, K, 2008
)
0.35
" However, by means of pharmacokinetic modeling we describe the inverse correlation between lipid solubility of a molecule and its active transport by placental ABC efflux transporters."( Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility.
Ceckova, M; Cygalova, LH; Hofman, J; Staud, F, 2009
)
0.35
" Pharmacokinetic parameters of losartan and EXP-3174 in rats were determined after oral and intravenous administration of losartan (9 mg/kg) without and with HMG-CoA reductase inhibitors (1 mg/kg)."( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Choi, DH; Choi, JS; Yang, SH, 2011
)
0.37
" The pharmacokinetic parameters of repaglinide and blood glucose concentrations were also determined in rats after oral (0."( Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
Choi, DH; Choi, JS; Li, C, 2012
)
0.38
"This pharmacodynamic trial evaluated the effect of CBT-1® on efflux by the ATP binding cassette (ABC) multidrug transporter P-glycoprotein (Pgp/MDR1/ABCB1) in normal human cells and tissues."( A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Barnett, D; Bates, SE; Caluag, Z; Chen, CC; Draper, D; Fojo, T; Frye, AR; Kelly, RJ; Luchenko, V; Oldham, RK; Robey, RW; Steinberg, SM, 2012
)
0.38
" This pharmacodynamic study demonstrated that CBT-1®, inhibits Pgp-mediated efflux from PBMCs and normal liver."( A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Barnett, D; Bates, SE; Caluag, Z; Chen, CC; Draper, D; Fojo, T; Frye, AR; Kelly, RJ; Luchenko, V; Oldham, RK; Robey, RW; Steinberg, SM, 2012
)
0.38
" But, when drugs were ranked for inhibitory potency, this order is reflected in pharmacodynamic changes or vice versa."( In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.
Drewe, J; Gutmann, H; Hiemke, C; Kirschbaum, KM; Kusch-Poddar, M; Poller, B; Schmitt, U, 2012
)
0.38
" Pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of licochalcon A (0."( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
Choi, DH; Choi, JS, 2013
)
0.39
"We determined the pharmacokinetic parameters of nifedipine and dehydronifedipine in rats after oral and intravenous administration of nifedipine without and with HMG-CoA reductase inhibitors."( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Choi, DH; Choi, JS; Lee, CK, 2015
)
0.42
" Pharmacokinetic interactions may be caused by modulation of efflux transporter proteins, intercellular tight junctions and/or metabolic enzyme amongst others."( Excipient-drug pharmacokinetic interactions: Effect of disintegrants on efflux across excised pig intestinal tissues.
Gerber, W; Hamman, JH; Steyn, JD, 2018
)
0.48
" To assess the pharmacokinetic profile of daclatasvir in vivo, rats were divided into three groups receiving either saline, standard P-gp inhibitor verapamil (25 mg/kg), or atorvastatin (10 mg/kg), 2 hrs prior to a single dose of daclatasvir (7 mg/kg)."( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450.
El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022
)
0.72
" In vivo, Cmax (peak plasma concentration) and area under the curve (AUC (0-t)) of daclatasvir after atorvastatin treatment increased compared to the vehicle group but not in a significant manner."( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450.
El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The results suggest a potential role for R123 in combination with hyperthermia in the treatment of malignant cells."( In vitro and in vivo cytotoxicity of rhodamine 123 combined with hyperthermia.
Chase, D; Goffney, WH; Kern, DH; Krag, DN; Storm, FK; Wong, JH, 1990
)
0.28
" Glucose deprivation induced by insulin, and combined with the inhibition of oxidative phosphorylation, produces an additive depression of tumor energetics."( Inhibition of tumor high-energy phosphate metabolism by insulin combined with rhodamine 123.
Arbeit, JM; Hubesch, A; Karczmar, GS; Toy, BJ; Weiner, MW, 1988
)
0.27
" Prenatal mortality was increased by Rh 123 in combination with 2-DOG, with values of 40%, 43%, or 41% dead or resorbed at Rh 123 doses of 8, 12, or 15 mg/kg/day, respectively."( Teratogenic effects of a lipophilic cationic dye rhodamine 123, alone and in combination with 2-deoxyglucose.
Hood, RD; Jones, CL; Ranganathan, PN; Ranganathan, S, 1988
)
0.27
" No correlation was observed between the ABCB1 C3435T, G2677T/A, and C1236T polymorphisms, separately and in haplotypes, with saquinavir pharmacokinetics, administered with or without ritonavir and with PBMC P-gp expression and activity."( The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
Béïque, L; Cameron, DW; Chauhan, B; Foster, BC; Garber, GE; la Porte, CJ; Li, Y; van Heeswijk, RP, 2007
)
0.34
" Inhibition or induction of P-gp can cause drug-drug interactions and thus influence the effects of P-gp substrate drugs."( 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Ai, H; Gu, Y; Hao, G; Li, Y; Peng, Y; Sun, J; Wang, G; Wu, X; Zhang, J; Zhang, X; Zheng, Y; Zhou, F, 2010
)
0.36
" Combined with its ease of administration and lack of toxicity, the data showing inhibition of normal tissue Pgp support further studies with CBT-1® to evaluate its ability to modulate drug uptake in tumor tissue."( A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Barnett, D; Bates, SE; Caluag, Z; Chen, CC; Draper, D; Fojo, T; Frye, AR; Kelly, RJ; Luchenko, V; Oldham, RK; Robey, RW; Steinberg, SM, 2012
)
0.38
"Antimalarials are widely used in African and Southeast Asian countries, where they are combined with other drugs for the treatment of concurrent ailments."( Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells.
Horie, T; Oga, EF; Sekine, S; Shitara, Y, 2012
)
0.38
"This study was devised to investigate if P-glycoprotein (P-gp) mediated the drug-drug interaction (DDI) between genistein and repaglinide."( Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp.
Huo, X; Jin, H; Liu, K; Ma, X; Meng, Q; Sun, H; Sun, P; Tan, A; Wang, C; Wu, J; Zhu, Y, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic experiments show oral bioavailability through gastric absorption."( Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
Cescon, DW; Hansen, MD; Hoj, JP; Siddiqui-Jain, A, 2018
)
0.48
" Thus the interpretation of results of clinical 'modulator' trials should consider the decreased bioavailability of MDR-reversing agents."( Decreased potency of MDR-modulators under serum conditions determined by a functional assay.
Eisterer, W; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J, 1995
)
0.29
" Impairment of glucose bioavailability reduced Rh 123 fluorescence."( Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry.
Camarasa, J; Camins, A; Comas, J; Escubedo, E; Gabriel, C; Sureda, FX, 1997
)
0.3
" These results suggest that enhanced oral bioavailability of drugs co-administered with TPGS may, in part, be due to inhibition of P-glycoprotein in the intestine."( Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).
Dintaman, JM; Silverman, JA, 1999
)
0.3
" This may lead to increased bioavailability of coadministered compounds."( Methadone inhibits rhodamine123 transport in Caco-2 cells.
Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL, 2001
)
0.31
" Chronic use of Saint John's wort (SJW) has been shown to lower the bioavailability for a variety of co-administered drugs including indinavir, cyclosporin, and digoxin."( Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
Greenblatt, DJ; Perloff, MD; Shader, RI; Störmer, E; von Moltke, LL, 2001
)
0.31
" Thus, GTPs or EGCG might be potential agents for modulating the bioavailability of P-gp substrates at the intestine and the multidrug resistance phenotype associated with expression of this transporter in cancer cells."( Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols.
Beliveau, R; Demeule, M; Jodoin, J, 2002
)
0.31
" This work also describes the effects of IL2 on the oral bioavailability of a Pgp substrate (digoxin) and of a Pgp/CYP3A cosubstrate (saquinavir)."( Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice.
Banide, H; Faivre, L; Farinotti, R; Lacour, B; Soursac, M; Tardivel, S; Veau, C, 2002
)
0.31
" Therefore, they may enhance the oral bioavailability of P-gp substrates by increasing absorption in the small intestine."( Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates.
Koyabu, N; Matsuo, H; Ohtani, H; Sawada, Y; Takanaga, H; Tian, R, 2002
)
0.31
" Thus, to accurately determine the absorption rate of Rho123, it was necessary to measure the water movement."( Regional difference in P-glycoprotein function in rat intestine.
Hayashi, M; Iida, A; Tomita, M, 2005
)
0.33
" This in vivo study showed that a delivery system based on thiolated chitosan significantly increased the oral bioavailability of P-gp substrate Rho-123."( In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan.
Bernkop-Schnürch, A; Föger, F; Schmitz, T, 2006
)
0.33
" This in vivo study showed that polymeric P-gp inhibitors and especially the delivery system based on thiolated chitosan significantly increased the oral bioavailability of P-gp substrate Rho-123."( In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein.
Bernkop-Schnürch, A; Föger, F; Hoyer, H; Kafedjiiski, K; Thaurer, M, 2006
)
0.33
" These results indicate that extracts and flavone derivatives from the rhizome of Kaempferia parviflora can inhibit P-gp function, which may be useful for overcoming P-gp-mediated multidrug resistance and improving the oral bioavailability of anticancer agents."( Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function.
Murakami, T; Nagai, J; Patanasethanont, D; Sripanidkulchai, BO; Sutthanut, K; Takano, M; Yenjai, C; Yumoto, R, 2007
)
0.34
" In conclusion, ginger significantly decreased the oral bioavailability of cyclosporine, and the interaction should occur at the absorption phase."( Ginger significantly decreased the oral bioavailability of cyclosporine in rats.
Chao, PD; Chiang, HM; Hou, YC; Hsiu, SL; Tsai, SY; Wen, KC, 2006
)
0.33
" These findings suggest that low concentrations of Labrasol might inhibit the function of P-gp in the intestine, thereby increasing intestinal absorption and bioavailability of P-gp substrates including rhodamine123."( Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats.
Fujita, T; Jiang, X; Katsumi, H; Lin, Y; Okada, N; Shen, Q; Yamamoto, A, 2007
)
0.34
" Lipid excipients are increasingly used as drug delivery systems for hydrophobic drugs to increase their bioavailability by overcoming the barrier of low absorption."( Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Lee, SD; Sachs-Barrable, K; Thamboo, A; Wasan, KM, 2007
)
0.34
" The results suggest a new mechanism which may contribute to the improved bioavailability seen for drugs formulated with lipid-based excipients."( Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Lee, SD; Sachs-Barrable, K; Thamboo, A; Wasan, KM, 2007
)
0.34
" Thus, a functional interplay between membrane Gb3 and MDR1 provides a more physiologically based approach to MDR1 regulation to increase the bioavailability of chemotherapeutic drugs."( Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
Ackerley, C; Clarke, DM; De Rosa, MF; Ito, S; Lingwood, C; Wang, B, 2008
)
0.35
" In addition, the effects of DHA on in vitro midazolam metabolism in rat intestinal microsomes and on midazolam bioavailability in rats were examined."( Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich, V; Murakoso, K; Sato, H, 2008
)
0.35
"Low concentrations of Tween-80 may promote the absorption of P-gp-mediated drugs and therefore improve the oral bioavailability of these drugs."( [Effect of Tween-80 on the permeability of rhodamine 123, a P-gp substrate across rat intestinal membranes in vitro].
Guo, D; Li, GF; Tan, YF; Wang, L, 2008
)
0.35
" The oral bioavailability of paclitaxel in TPGS 400/ethanol (7."( Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice.
Chang, YW; Chao, YS; Chen, CT; Chiang, TH; Ho, PY; Lin, HL; Lo, YK; Wu, HY; Wu, SH; Yao, HT; Yeh, TK, 2008
)
0.35
"Oral drug development had been hindered by the bioavailability issue despite vast market popularity."( Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells.
Jia, JX; Wasan, KM, 2008
)
0.35
" Subsequently, TPPG 1000 was tested for its ability to enhance the bioavailability of raloxifene - an established P-gp substrate -in fasted male rats."( Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.
Buchanan, CM; Caflisch, GB; Edgar, KJ; Large, SE; Lightner, JW; Little, JL; Rice, PJ; Ruble, KM; Wacher, VJ; Wempe, MF; Wright, C, 2009
)
0.35
"The present study aimed to assess the effect of resveratrol on the bioavailability of nicardipine in rats."( Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol.
Choi, BC; Choi, JS; Kang, KW, 2009
)
0.35
" In conclusion, PS is potentially useful as a pharmaceutical ingredient to improve the oral bioavailability of coadministered P-gp substrates and substrates for certain CYP isoforms."( Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450.
Hong, M; Hu, Z; Huang, R; Jiang, Y; Liu, C; Pei, Y; Zhu, S, 2009
)
0.35
" Intestinal cells constitute a first barrier to mycotoxins exposure, since they express membrane ABC transporters that may affect the bioavailability of food xenobiotics."( ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites.
Delaforge, M; Lecoeur, S; Mazallon, M; Prouillac, C; Videmann, B, 2009
)
0.35
" P-gp is a drug transporter, which determines the absorption and bioavailability of many drugs that are substrates for P-gp."( Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu, M; Naruhashi, K; Nishimura, A; Prabha, T; Shibata, N; Sugioka, N; Takada, K, 2009
)
0.35
"The purpose of this thesis is to investigate the effects of baicalein, an antioxidant, on the bioavailability and pharmacokinetics of Doxorubicin (DOX) in rats."( Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein.
Choi, JS; Li, C; Shin, SC, 2009
)
0.35
" Consequently, the absolute bioavailability (AB) of tamoxifen in the presence of silybinin (2."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
" Rhei Rhizoma extract (100 microg/ml) significantly suppressed the CYP3A-mediated 6beta-hydroxylation of testosterone in hepatic microsomes, and increased the extent of bioavailability of midazolam, a typical CYP3A substrate, in rats."( Interaction of Rhei Rhizoma extract with cytochrome P450 3A and efflux transporters in rats.
Akashi, H; Kida, M; Mori, M; Mori, N; Murakami, T; Yokooji, T; Yoshihara, S, 2010
)
0.36
" Surfactants, known pharmaceutically to alter membrane permeability, change drug bioavailability and attenuate transporter function are also found in contaminant mixtures in the aquatic environment."( Enhanced bioaccumulation of dietary contaminants in catfish with exposure to the waterborne surfactant linear alkylbenzene sulfonate.
Kleinow, KM; Tan, X; Uppu, P; Yim, SY, 2010
)
0.36
" This model also has application for the screening of drug candidates for effects on oral bioavailability via effects on the subcellular distribution and trafficking of P-gp."( Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells.
Allen, J; Bebawy, M; Kota, BP; Roufogalis, BD; Tran, VH, 2010
)
0.36
" Consequently, the absolute bioavailability of loratadine in the presence of silybinin (1."( Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
Choi, JS; Lee, MY; Li, C, 2010
)
0.36
" Compared with the control group (given etoposide alone), curcumin (2 or 8 mg/kg) increased significantly the oral bioavailability (AUC and C(max) ) of etoposide."( Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Choi, JS; Ki, SH; Lee, CK, 2011
)
0.37
"These thiolated chitosans would therefore be advantageous tools for enhancing the noninvasive bioavailability of active pharmaceutical ingredients."( Thiolated chitosans: influence of various sulfhydryl ligands on permeation-enhancing and P-gp inhibitory properties.
Bernkop-Schnürch, A; Iqbal, J; Millotti, G; Sakloetsakun, D; Vetter, A, 2011
)
0.37
" Consequently, the absolute bioavailability (F) of losartan after oral administration with simvastatin was significantly increased by 59."( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Choi, DH; Choi, JS; Yang, SH, 2011
)
0.37
"As the most prevalent route of delivery, oral administration has the challenge of potentially low bioavailability in part because P-glycoprotein (P-gp) in the intestinal tract affects absorption."( Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats.
He, H; Li, J; Shen, Q, 2011
)
0.37
" Collectively, these results obtained from the present study demonstrated that P123 and F127 were capable of inhibiting the intestinal P-gp activity, but had little or no effect on intestinal cytochrome P450 3A activity, indicating that P123 and F127 can potentially be used as pharmaceutical ingredients to improve the oral bioavailability of coadministered P-gp substrates via P-gp efflux pump inhibition."( Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism.
Guan, Y; Huang, J; Li, G; Qiu, J; Si, L; Xu, J; Zuo, L, 2011
)
0.37
"As an inhibitor of CYP2C9, CYP2D6 and P-gp, myricetin might affect the bioavailability of carvedilol when myricetin and carvedilol are used concomitantly for the prevention or therapy of cardiovascular diseases as a combination therapy."( Effects of myricetin on the bioavailability of carvedilol in rats.
Choi, JS; Lee, W; Woo, ER, 2012
)
0.38
"The enhanced oral bioavailability of carvedilol may result from both inhibition of CYP2C9 or CYP2D6-mediated metabolism and P-gp-mediated efflux of carvedilol in small intestine and/or in liver by myricetin rather than reducing renal elimination."( Effects of myricetin on the bioavailability of carvedilol in rats.
Choi, JS; Lee, W; Woo, ER, 2012
)
0.38
"01 for 3 mg/kg) increased the absolute bioavailability (AB) of repaglinide by 51."( Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
Choi, DH; Choi, JS; Li, C, 2012
)
0.38
"P-glycoprotein (P-gp) is an efflux transporter that regulates bioavailability of orally administered drugs at the intestinal epithelium."( Real-time analysis of P-glycoprotein-mediated drug transport across primary intestinal epithelium three-dimensionally cultured in vitro.
Fukuda, M; Mizutani, T; Mochizuki, W; Morikawa, R; Nagaishi, T; Nakamura, T; Nemoto, Y; Nozaki, K; Okamoto, R; Tsuchiya, K; Watanabe, M; Yamauchi, Y; Yui, S, 2012
)
0.38
" Hence, infection and inflammatory diseases may induce variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters."( Suppression of efflux transporters in the intestines of endotoxin-treated rats.
Hatanaka, M; Hayashi, M; Kai, T; Kanbayashi, A; Murata, H; Nakaike, M; Takizawa, Y; Tanaka, A; Tomita, M, 2012
)
0.38
"The effects of curcumin, a natural anti-cancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its metabolite, 4-hydroxytamoxifen, were investigated in rats."( Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Cho, YA; Choi, JS; Lee, W, 2012
)
0.38
" In our preliminary study, notoginsenoside R₁ was able significantly to improve the bioavailability of geniposide in beagle dogs, but the underlying mechanisms remain unknown."( The effects of notoginsenoside R₁ on the intestinal absorption of geniposide by the everted rat gut sac model.
Chula, S; Hang, L; Jianning, S; Shi, R; Yinying, B, 2012
)
0.38
" However, low oral bioavailability limited its application."( Curcuma increasing antitumor effect of Rhizoma paridis saponins through absorptive enhancement of paridis saponins.
Fan, W; Gao, W; Li, N; Li, Y; Liu, C; Liu, Z; Man, S; Zhang, Y, 2013
)
0.39
" Consequently, the absolute bioavailability of losartan in the presence of licochalcon A increased significantly (2."( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
Choi, DH; Choi, JS, 2013
)
0.39
" In situ intestinal perfusion experiments also showed that CK, Ppd, and Ppt increased the absorption rate constant and permeability coefficient of rhodamine 123."( Ginsenoside metabolites inhibit P-glycoprotein in vitro and in situ using three absorption models.
Ge, G; Li, N; Liu, Y; Wang, D; Wang, X; Yang, L, 2014
)
0.4
" However, its oral bioavailability has not been known."( Permeability of rhynchophylline across human intestinal cell in vitro.
Li, M; Ma, B; Sun, G; Sun, J; Sun, X; Wang, J; Xu, H, 2014
)
0.4
" These findings have to be taken into consideration when DAPP is concurrently given with other drugs that are substrates for P-gp since drug-drug interactions harbour a safety issue and alter bioavailability profiles."( The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells.
Darlington, JW; Sachs-Barrable, K; Wasan, KM, 2014
)
0.4
" In summary, trantinterol is a potent noncompetitive P-gp inhibitor which may increase the bioavailability of other P-gp substrate drugs coadministered with it."( Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo.
Fan, H; Fawcett, JP; Gu, J; Guo, Y; Liu, J; Ma, W; Sun, Y; Wang, T; Yang, J; Yang, Y; Yang, Z, 2015
)
0.42
"The increased bioavailability of nifedipine may be mainly due to inhibition of both P-gp in the small intestine and CYP3A subfamily-mediated metabolism of nifedipine in the small intestine and/or in the liver and to the reduction of the CL/F of nifedipine by fluvastatin and simvastatin."( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Choi, DH; Choi, JS; Lee, CK, 2015
)
0.42
" Thus, their bioavailability could be affected by changes in this transporter."( Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Celuch, SM; Ghanem, CI; Godoy, YC; Martinez, SA; Novak, A, 2015
)
0.42
"The present study demonstrated that MetS-like conditions generated by enhanced fructose intake in rats decreased the protein expression and activity of ileal P-gp, thus increasing the bioavailability of P-gp substrates."( Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Celuch, SM; Ghanem, CI; Godoy, YC; Martinez, SA; Novak, A, 2015
)
0.42
" Concurrent administration of P-gp inhibitors and P-gp substrate drugs may also result in alterations in the bioavailability of some antimalarials."( The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.
Crowe, A; Page-Sharp, M; Senarathna, SM, 2016
)
0.43
"P-glycoprotein (P-gp), as the most important efflux transporter in intestines, plays the key role to determine the bioavailability of many drugs."( Measurement of Rhodamine 123 in Three-Dimensional Organoids: A Novel Model for P-Glycoprotein Inhibitor Screening.
Li, D; Liu, M; Wang, X; Zeng, Z; Zhang, Y; Zhao, J, 2016
)
0.43
" P-gp inhibitors could serve as helpful tools to enhance the oral bioavailability of those substances."( The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
Burhenne, J; Fricker, G; Mylius, P; Schubert, R; Weinheimer, M, 2017
)
0.46
"P-glycoprotein (P-gp), an important efflux transporter in intestine, regulates the bioavailability of orally taken drugs."( A Novel Model of P-Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids.
Li, D; Liu, M; Sun, J; Wang, X; Zeng, Z; Zhang, X; Zhang, Y; Zhao, J, 2017
)
0.46
" Abemaciclib (LY2835219) is an orally bioavailable CDK4/6 inhibitor under phase III clinical trials."( Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Chen, Z; Cheng, B; Fang, X; Fu, L; To, KKW; Wang, F; Wu, T, 2017
)
0.46
"Currently, the most prominent barrier to the success of orally delivered paclitaxel (PTX) is the extremely limited bioavailability of delivered therapeutic."( N-Deoxycholic acid-N,O-hydroxyethyl Chitosan with a Sulfhydryl Modification To Enhance the Oral Absorptive Efficiency of Paclitaxel.
Cai, H; Chen, Q; Fu, Y; Huo, M; Mu, Y; Xu, W; Yao, L; Yin, T; Yu, Y; Zhou, J, 2017
)
0.46
" One major factor that contributes to low bioavailability are efflux transporters which prevent drug absorption through intestinal epithelial cells."( Reversible inhibition of efflux transporters by hydrogel microdevices.
Desai, TA; Kroetz, DL; Lamson, NG; Levy, ES; Samy, KE; Whitehead, KA, 2019
)
0.51
"P-glycoprotein (P-gp) over-expression plays a vital role in not only systemic drug bioavailability but also cancer multi-drug resistance (MDR)."( A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Hung, CC; Lan, YH; Lin, KI; Lin, YC; Teng, YN; Thang, TD, 2021
)
0.62
"Atorvastatin has a significant effect on P-gp mediated intestinal transport of daclatasvir; however, it did not affect the systemic bioavailability of a single oral dose of daclatasvir."( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450.
El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022
)
0.72
" An anti-amyloidogenic bis-styrylbenzene derivative, KMS80013, showed excellent oral bioavailability (F=46."( Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
Ahn, YG; Byeon, SR; Jeon, M; Kim, DJ; Kim, HV; Kim, HY; Kim, MS; Kim, YS; Kong, JY, 2013
)
0.39

Dosage Studied

Rhodamine 123 was given at a dosage of 15 mg/kg every other day for 33 to 38 days. After five days culture, hepatocytes were incubated with a dosing solution including CDF or Rhodamine 123.

ExcerptRelevanceReference
" irradiation at the posterior of early cleavage embryos at a sufficient dosage to prevent pole cell formation."( Spatial and developmental changes in the respiratory activity of mitochondria in early Drosophila embryos.
Akiyama, T; Okada, M, 1992
)
0.28
" Similarly dosed conscious animals (without surgical intervention) housed in metabolic cages showed a comparable pattern of urinary excretion, with 11."( Metabolism and elimination of rhodamine 123 in the rat.
Israel, M; Seshadri, R; Sweatman, TW, 1990
)
0.28
"Significant destruction of the Pollard III rat prostate adenocarcinoma was achieved by treatment with rhodamine 123 at a dosage of 15 mg/kg every other day for 33 to 38 days."( Use of rhodamine 123 in the treatment of the Pollard III rat prostate adenocarcinoma.
Arcadi, JA, 1990
)
0.28
" The resulting dose-survival curve was identical to the dose-response curve of RS cells treated with R123 alone."( Relationship between cellular accumulation of rhodamine 123 (R123) and cytotoxicity in B16 melanoma cells.
Gan, L; Krag, DN; Tao, SZ; Theon, AP; Wardell, J, 1989
)
0.28
" Rhodamine was administered subcutaneously every other day at a dosage of 15 mg/Kg body weight for fifty-two days."( Rhodamine-123 as effective agent in rat prostate tumor R3327-H. Preliminary report.
Arcadi, JA, 1986
)
0.27
" The cybrids were then selected in the presence of various concentrations of CAP to examine the effect of donor mitochondrial dosage on the transfer of CAP resistance."( Effect of mitochondrial dosage on transfer of chloramphenicol resistance.
Shay, JW; Walker, C, 1983
)
0.27
" Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line."( Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994
)
0.29
" These latter findings are important for establishing the dosing regimens of LY335979 for future clinical studies."( Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.
Green, LJ; Marder, P; Slapak, CA, 2001
)
0.31
" These results provide evidence that esiRNA of MDR1 could be an alternative to P-gp inhibitors with the advantage of avoiding non-specific suppression with a lower effective dosage than using a single siRNA duplex, offering a potential therapeutic application of siRNA."( Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA.
Huang, W; Li, L; Min, T; Xu, J, 2006
)
0.33
" The inhibitory potency of the tested drugs from the dose-response relationships was cyclosporin A>verapamil> phenytoin> carbamazepine> lamotrigine>phenobarbital>valproic acid, levetiracetam, gabapentin."( Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs.
Chen, CC; Hung, CC; Lin, CJ; Liou, HH, 2008
)
0.35
" Animals dosed with raloxifene and TPPG 1000 experienced an increase in raloxifene oral bioavailability versus a control group which received no inhibitor."( Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.
Buchanan, CM; Caflisch, GB; Edgar, KJ; Large, SE; Lightner, JW; Little, JL; Rice, PJ; Ruble, KM; Wacher, VJ; Wempe, MF; Wright, C, 2009
)
0.35
" Based on these results, nicardipine dosage should be adjusted when given with supplements containing resveratrol."( Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol.
Choi, BC; Choi, JS; Kang, KW, 2009
)
0.35
" This information on melatonin absorption behaviors and its modulation by pharmaceutical excipients can be used in further oral dosage formulations to affect circadian rhythm."( New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing chamber technique with mounted rat gastrointestinal segments.
Lee, BJ; Tran, HT; Tran, PH, 2009
)
0.35
" dosage forms."( Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein.
Choi, JS; Li, C; Shin, SC, 2009
)
0.35
" If these results are confirmed in clinical trials, the tamoxifen dosage should be adjusted when tamoxifen is administered with silybinin or silybinin-containing dietary supplements."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
" For dose-response studies, LS-180 cells were treated with different concentrations of the selected drugs followed by P-gp protein and gene expressions analyses."( Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.
Abuznait, AH; Kaddoumi, A; Patrick, SG, 2011
)
0.37
" A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity."( Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.
Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011
)
0.37
" If the present rat data could be expressed to humans, the alterations in docetaxel absorption and metabolism should be considered in designing a dosage regimen for cancer patients with PCM state after cysteine supplement."( Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein-calorie malnutrition.
Choi, YH; Kim, YG; Lee, MG; Yoon, I, 2012
)
0.38
" These results may provide a possible explanation for higher methadone dosage requirements in patients carrying variant-type of P-gp and revealed the possible drug-drug interactions in patients who receive concomitant drugs which are also P-gp substrates."( Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone.
Chiou, MH; Hsieh, YW; Huang, CL; Hung, CC; Lane, HY; Teng, YN, 2013
)
0.39
" These findings stipulate the importance of using multiphoton microscopy to understand transmembrane drug flux and reflect on careful drug dosing after hepatic surgery."( Effects of long-term hepatic ischemia-reperfusion injury on the function of P-glycoprotein in vivo in rats.
Burczynski, FJ; Crawford, D; Fletcher, LM; Liu, X; Roberts, MS; Thorling, CA, 2014
)
0.4
" After five days culture, the hepatocytes were incubated with a dosing solution including CDF or Rhodamine 123."( Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure.
Ichikawa, H; Kanda, K; Takahashi, R, 2016
)
0.43
" The findings suggested that the DDI between genistein and repaglinide is mediated by P-gp, and a dosage adjustment may be needed when they are co-administered in a clinical setting."( Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp.
Huo, X; Jin, H; Liu, K; Ma, X; Meng, Q; Sun, H; Sun, P; Tan, A; Wang, C; Wu, J; Zhu, Y, 2020
)
0.56
"05) changed under certain dosage conditions of pharmaceutical excipients such as sodium carboxymethyl starch, pullulan, glyceryl monostearate and so on."( Influene of Pharmaceutical Excipients on the Membrane Transport of a P-glycoprotein Substrate in the Rat Small Intestine.
Furuya, T; Goto, N; Hayashi, M; Takizawa, Y, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
fluorochromeA fluorescent dye used to stain biological specimens.
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organic chloride salt
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
organic cationAny organic ion with a net positive charge.
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
organic chloride salt
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Ki10.11000.11002.02675.5000AID681382
ATP-dependent translocase ABCB1Homo sapiens (human)Ki23.40003.40003.40003.4000AID681382
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)Kact4.50001.00003.75007.0000AID678804
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID1374482Apparent intrinsic permeability in human Caco2 cells from apical to basolateral side after 120 mins in presence of P-gp inhibitor by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1472417Apparent permeability across apical to basolateral side in human Caco2 cells at 100 uM after 20 mins by fluorescein dye based HPLC-UV analysis2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1374483Apparent intrinsic permeability in human Caco2 cells from basolateral to apical side after 120 mins in presence of P-gp inhibitor by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1374481Efflux ratio of apparent intrinsic permeability in human Caco2 cells after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1473283Efflux ratio of apparent permeability from in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1854258Stability in human Jurkat lymphocytes assessed as half life in mitochondria at 10 uM incubated for 1 hrs by flow cytometry2022RSC medicinal chemistry, Apr-20, Volume: 13, Issue:4
Synthesis of a fluorinated pyronin that enables blue light to rapidly depolarize mitochondria.
AID1374480Apparent intrinsic permeability in human Caco2 cells from basolateral to apical side after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1472418Apparent permeability across basolateral to apical side in human Caco2 cells at 100 uM after 20 mins by fluorescein dye based HPLC-UV analysis2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1472447Apparent permeability across basolateral to apical side in human Caco2 cells after 20 mins in presence of ABCB1 inhibitor PSC833 by HPLC-UV analysis2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1374479Apparent intrinsic permeability in human Caco2 cells from apical to basolateral side after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1374484Efflux ratio of apparent intrinsic permeability in human Caco2 cells after 120 mins in presence of P-gp inhibitor by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1473280Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1473281Apparent permeability from apical to basolateral side in human Caco2 cells assessed as drug recovery at 10 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1760013Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells2021European journal of medicinal chemistry, Jul-05, Volume: 219Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
AID1759973Apparent permeability across basolateral to apical in human Caco2 cells by LC-MS/MS analysis2021European journal of medicinal chemistry, Jul-05, Volume: 219Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
AID1472419Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1473282Apparent permeability from basolateral to apical side in human Caco2 cells assessed as drug recovery at 10 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1472446Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells in presence of ABCB1 inhibitor PSC8332018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1472448Apparent permeability across apical to basolateral side in human Caco2 cells after 20 mins in presence of ABCB1 inhibitor PSC833 by HPLC-UV analysis2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1473279Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1759974Apparent permeability across apical to basolateral in human Caco2 cells by LC-MS/MS analysis2021European journal of medicinal chemistry, Jul-05, Volume: 219Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2005Molecular pharmacology, Nov, Volume: 68, Issue:5
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2016Clinical pharmacology and therapeutics, Nov, Volume: 100, Issue:5
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
AID681613TP_TRANSPORTER: intracellular accumulation in MDR1-expressing LLC-PK1 cells2000Molecular pharmacology, Jan, Volume: 57, Issue:1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID681148TP_TRANSPORTER: inhibitory effect of typical BSEP inhibitors (Verapamil & Cyclosporin A) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID572062Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID336106Cytotoxicity against multidrug-resistant human KBV1 cells by MTS/PMS assay2002Journal of natural products, Sep, Volume: 65, Issue:9
In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells.
AID572058Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID681382TP_TRANSPORTER: inhibition of Verapamil binding in membranes from Vinblastine-induced Caco-2 cells1999The Journal of pharmacology and experimental therapeutics, Jan, Volume: 288, Issue:1
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
AID160054In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR32002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID310118Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
New functional assay of P-glycoprotein activity using Hoechst 33342.
AID358276Cytotoxicity against multidrug-resistant human KBV1 cells after 48 hrs by MTS/PMS assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones.
AID572061Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC00372009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID680870TP_TRANSPORTER: intracellular accumulation in mdr1b-expressing NIH3T3 cells1997Carcinogenesis, Nov, Volume: 18, Issue:11
Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates.
AID554738Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 131 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID376733Resistance index, ratio of IC50 for human KBV1 cells to IC50 for human KB31 cells2000Journal of natural products, Nov, Volume: 63, Issue:11
Cytotoxic activity of some phenanthroindolizidine N-oxide alkaloids from Cynanchum vincetoxicum.
AID358275Cytotoxicity against drug-sensitive human KB-3-1 cells after 48 hrs by MTS/PMS assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID72013Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID680116TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells2004Journal of pharmaceutical sciences, May, Volume: 93, Issue:5
Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
AID681566TP_TRANSPORTER: intracellular accumulation in Bsep-expressing LLC-PK1 cells2000Molecular pharmacology, Jan, Volume: 57, Issue:1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID679284TP_TRANSPORTER: intracellular accumulation in K562 and K562/DXR cells2000Methods and findings in experimental and clinical pharmacology, Jun, Volume: 22, Issue:5
Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
AID680129TP_TRANSPORTER: transepithelial transport (basal to apical) in HCT-8 cells1998The Journal of pharmacology and experimental therapeutics, Sep, Volume: 286, Issue:3
Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
AID310119Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
New functional assay of P-glycoprotein activity using Hoechst 33342.
AID358278Resistance index, ratio of IC50 for multidrug-resistant human KBV1 cells to IC50 for drug-sensitive human KB-3-1 cells2001Journal of natural products, Nov, Volume: 64, Issue:11
Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones.
AID571882Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID571884Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID572059Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID336105Cytotoxicity against drug-resistant human KB-3-1 cells by MTS/PMS assay2002Journal of natural products, Sep, Volume: 65, Issue:9
In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells.
AID376731Cytotoxicity against drug-resistant human KB31 cells after 72 hrs by MTS reduction assay2000Journal of natural products, Nov, Volume: 63, Issue:11
Cytotoxic activity of some phenanthroindolizidine N-oxide alkaloids from Cynanchum vincetoxicum.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID232807Selective toxicity- EC50 value of FM3A / EC50 value of Plasmodium falciparum2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID678963TP_TRANSPORTER: uptake in BCRP-expressing oocyte cells2003Molecular pharmacology, Dec, Volume: 64, Issue:6
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
AID572060Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID678905TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1998Pharmaceutical research, Nov, Volume: 15, Issue:11
BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123.
AID749133Apparent permeability from apical to basolateral side in mouse bEND.3 /rat C6 co-culture cell model after 1 hr by Transwell assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
AID336107Resistance index, ratio for IC50 for multidrug-resistant human KBV1 cells to IC50 for drug-resistant human KB-3-1 cells2002Journal of natural products, Sep, Volume: 65, Issue:9
In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells.
AID678964TP_TRANSPORTER: uptake in BCRP-expressing Lactococcus lactis cells2003The Journal of biological chemistry, Jun-06, Volume: 278, Issue:23
Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
AID376732Cytotoxicity against multidrug-resistant human KBV1 cells after 72 hrs by MTS reduction assay2000Journal of natural products, Nov, Volume: 63, Issue:11
Cytotoxic activity of some phenanthroindolizidine N-oxide alkaloids from Cynanchum vincetoxicum.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID678804TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells2001Biochemical and biophysical research communications, Jul-06, Volume: 285, Issue:1
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,700)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990127 (7.47)18.7374
1990's492 (28.94)18.2507
2000's587 (34.53)29.6817
2010's453 (26.65)24.3611
2020's41 (2.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.91 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index64.68 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (45.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials10 (0.57%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews21 (1.19%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.11%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other1,727 (98.13%)84.16%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]